KPV.
α-MSH C-terminal tripeptide with strong anti-inflammatory action.
Build your bag, then either book a consultation (an EU-licensed physician reviews your file — anything declined is refunded) or upload an existing Rx at checkout.
- ✓Magistral preparation — Directive 2001/83/EC Art. 5(1).
- ✓Patient-named prescription only — dispensed against a valid Rx.
- ✓EU-GMP Annex 1 Grade A/B cleanroom compounding.
- ✓Cold-chain shipping across EU/EEA — 2–5 working days.
About KPV.
KPV (Lysine-Proline-Valine) is the C-terminal tripeptide of α-MSH, retaining most of α-MSH's anti-inflammatory activity but with minimal pigmentary effect. It is particularly studied in mucosal and gut inflammation models.
KPV is commonly used as an adjunct in IBD-type protocols and skin or oral mucosal inflammation; the evidence base is mostly preclinical with growing clinical experience.
KPV inhibits the NF-κB inflammatory pathway and reduces pro-inflammatory cytokine release (TNF-α, IL-6). It also displays direct anti-microbial activity against several gut-relevant pathogens at micromolar concentrations.
Subcutaneous injection, typically 200–500 mcg per day for inflammatory or gut protocols, cycles of 4–8 weeks.
Your physician sets the prescription. This is descriptive information, not a self-administration guide.
Lyophilised: store at 2–8 °C, protect from light. Once reconstituted: 2–8 °C, use within 30 days. Do not freeze.
- INN / Name
- KPV
- Form
- Lyophilised vial · subcutaneous injection
- Strength
- 5mg vial
- Manufacturing
- EU-GMP Annex 1 · Grade A/B
- Endotoxins
- European Pharmacopoeia 2.6.14 · LAL assay
- Identity & purity
- HPLC + MS · > 98%
- Cold chain
- Validated 2–8 °C, monitored end-to-end
- Regulatory basis
- Directive 2001/83/EC · Article 5(1)
2–5 working days
EU / EEA cold-chain delivery, 2–8 °C monitored end-to-end with digital temperature log. Tracking link sent on dispatch.
Magistral preparation
Patient-named preparation under Directive 2001/83/EC Article 5(1). Dispensed exclusively against a valid EU prescription.
EU prescription recognition
Prescriptions written in one EU member state are recognised in others under Directive 2011/24/EU on cross-border healthcare.
Within Healing & Recovery.
- Cat. 01
BPC-157
Synthetic pentadecapeptide derived from human gastric juice — broad tissue-repair signalling.
€60.00 - Cat. 01
TB-500 (Thymosin Beta)
Synthetic version of Thymosin β-4 — actin regulation, angiogenesis and cell migration in injured tissue.
€60.00 - Cat. 01
SS-31 (Elamipretide)
Mitochondrial-targeted tetrapeptide — preserves cardiolipin under oxidative stress.
€25.00